The Medicare Part D prescription drug benefit represents the largest expansion of Medicare since the program's introduction 40 years ago. The impact of the Medicare Modernization Act (MMA) has forced the entire health care industry-including health plans, PBMs, and pharmaceutical manufacturers-to fundamentally change both their short-term and long-term business strategies.

With so much at stake, it’s no wonder that more and more healthcare executives have turned to the Gorman Health Group (GHG) for expert advice and help.

Our reputation in this industry is unmatched. But don’t take our word for it: Lehman Brothers has called us “"The leading consulting firm in Medicare Managed Care.” Our highly-experienced, veteran staff has more than 500 years of combined managed care business and federal regulatory experience. We take pride in being an expert model consultancy; rather than staffing projects with newly-minted MBA’s, we only send senior consultants to the field to meet your needs.

Since the MMA’s passage, GHG has brought dozens of Medicare Advantage (MA) plans, Prescription Drug Plans (PDPs) and Special Needs Plans (SNPs) to market. While our strength comes from having such close relationships with Medicare’s managed care organizations, our full-service consultancy serves all of Medicare and Medicaid’s private-sector partners. We are regarded as having spearheaded the creation and design of the Medicare Advantage PPO product, which many consider to be the future of managed care, as well as being an early advocate for plans having diverse product portfolios.